Discover how AbbVie investors that bought the anxiety over the loss of Humira exclusivity are sitting on massive gains. Read ...

Emraclidine was expected to be a blockbuster drug for AbbVie, and this development didn’t sit well with investors.

AbbVie’s promising pipeline and 3.95% dividend yield offer growth potential. Read why ABBV stock could thrive despite the Emraclidine trial failure.

As pharmaphorum recently reported, the entrance of biosimilars to Humira is a significant event ... as there is no increased safety risk or less efficacy. Celltrion was next to announce the ...

It’s a new era for AbbVie. For the first time in years, the company has a new top sales driver as Skyrizi has overtaken Humira in quarterly sales. Humira heir Skyrizi has been slowly creeping up ...

By partnering directly with manufacturers, the insurer aims to dramatically reduce the price of AbbVie's Humira, the world's top-selling drug, by up to 90%. Blue Shield's agreement with drug ...